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The epigenetic regulator TET2 is frequently mutated in hematological diseases. Mutations have been shown to arise in he-
matopoietic stem cells early in disease development and lead to altered DNA methylation landscapes and an increased risk
of hematopoietic malignancy. Here, we show by genome-wide mapping of TET2 binding sites in different cell types that
TET2 localizes to regions of open chromatin and cell-type–specific enhancers. We find that deletion of Tet2 in native hema-
topoiesis as well as fully transformed acute myeloid leukemia (AML) results in changes in transcription factor (TF) activity
within these regions, and we provide evidence that loss of TET2 leads to attenuation of chromatin binding of members of the
basic helix–loop–helix (bHLH) TF family. Together, these findings demonstrate that TET2 activity shapes the local chroma-
tin environment at enhancers to facilitate TF binding and provides an example of how epigenetic dysregulation can affect
gene expression patterns and drive disease development.
[Supplemental material is available for this article.]
The tet methylcytosine dioxygenase (also known as ten-eleven
translocation [TET]) enzymes (TET1-3) mediate active DNA deme-
thylation of cytosines in CG dinucleotides. This occurs by pro-
cessive TET-mediated oxidation of 5-methylcytosine (5mC) to
5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and
5-carboxylcytosine (5caC). The presence of 5hmCmay lead to pas-
sive replication-dependent loss of DNA methylation, whereas 5fC
and 5caC can be excised by thymine DNA glycosylase (TDG) and
be replaced by unmodified cytosine via the base-excision repair
(BER) pathway. Although targeting of TET1 to chromatin has
been investigated (Williams et al. 2011;Wu et al. 2011), themech-
anisms of TET2 recruitment to chromatin remain poorly under-
stood (for review, see Rasmussen and Helin 2016).
Loss-of-function mutations of TET2 have been found in pa-
tients with awide range of hematological diseases, including acute
myeloid leukemia (AML) (Scourzic et al. 2015).More recently, high
frequenciesofTET2mutationshavealsobeenobserved inaging-as-
sociated clonal hematopoiesis (Genovese et al. 2014; Jaiswal et al.
2014;Xie et al. 2014) and in thepoorly studieddisorder clonal cyto-
penia of unknown significance (Kwok et al. 2015; Hansen et al.
2016). In previous studies, we and others identified a role of TET2
in protecting enhancer elements from aberrant DNA methylation
(Hon et al. 2014; Lu et al. 2014; An et al. 2015; Rasmussen et al.
2015; Yamazaki et al. 2015). In addition, inhibitionof TETproteins
was shown to perturb chromatin architecture at enhancers in an
embryonal carcinoma cell line undergoing neuronal differentia-
tion (Mahé et al. 2017). Despite these results, direct TET2 binding
at enhancers in hematopoietic cells has not been reported. In
fact, previous studies mapping TET2 genome-wide occupancy in
embryonic stem (ES) cells noted significant TET2 binding at CpG
islands and promoters (Chen et al. 2013; Deplus et al. 2013; Peng
et al. 2016)or at promoter-distal SALL4Abinding sites located at en-
hancers (Xiong et al. 2016). These seemingly contradictory obser-
vations as well as the impact of aberrant DNA methylation at
enhancer elements in hematopoietic cells remains to be resolved.
Geneexpression is regulatedby transcription factors (TFs) that
bind DNA in a sequence-specific manner. Activation of a specific
gene locus depends both on concentration of individual TFs as
well as their ability to access the regulatory genomic elements
that control gene expression. TF binding outside gene promoters
is associated with low- or intermediate DNA methylation, enrich-
ment of specific histone marks (e.g., monomethylation at histone
H3 lysine 4 and acetylation of H3 lysine 27), as well as the presence
of anucleosome-depleted region (Stadler et al. 2011; Thurmanet al.
2012). Althoughmuchworkhas focusedonunderstanding the role
of aberrant TF expression in leukemia, less is known about the role
of the chromatin environment, and hence DNA methylation
(Blattler and Farnham 2013), in modulating TF access to their cog-
nate binding sites.7These authors contributed equally to this work.
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The occurrence of enhancer DNA hypermethylation and he-
matological malignancies upon TET2mutation suggests that DNA
methylation may pose a challenge for TF binding (Thurman et al.
2012). Although several TFs have been demonstrated to bind
methylated DNA and induce DNA hypomethylation (e.g., CTCF
and REST) (Lienert et al. 2011; Stadler et al. 2011), many TFs
show an inherent binding preference in vitro formotifs with either
methylated or unmethylated CpG sites (Hashimoto et al. 2014;
Wang et al. 2017; Yin et al. 2017). As an illustration of this, global
loss of DNA methylation in ES cells was shown to unmask previ-
ously inaccessible genomic binding sites for the TF NRF1
(Domcke et al. 2015). Moreover, DNAmethylation and TET-medi-
ated oxidation products potentially influence binding of epigenet-
ic “readers” (e.g., Methyl-Binding Domain [MBD] proteins) (Song
and Pfeifer 2016), histone variants and nucleosome remodeling
enzymes (Conerly et al. 2010; Brunelle et al. 2015), and modify
the physical properties of chromatin and the shape of DNA itself
(Ngo et al. 2016).
Here, we generate and analyze genomic profiles from ES cells
and several hematopoietic cell types to understand the mecha-
nisms by which loss of TET2, and the resulting altered DNAmeth-
ylation landscape, affects gene expression patterns and promotes
the onset of hematological malignancies.
Results
Depletion of TET2 in ES and hematopoietic cells results in wide-
spread changes in the DNA methylation landscape (Ko et al.
2010; Asmar et al. 2013; Hon et al. 2014; An et al. 2015;
Rasmussen et al. 2015; Yamazaki et al. 2015). However, it still re-
mains unclear which regions are directly targeted by TET2 as op-
posed to being altered due to secondary effects of its depletion.
Previous studies, in our laboratory andothers, havebeenhampered
by chromatin immunoprecipitation (ChIP) artifacts—recently
coined as “Phantom peaks” (Jain et al. 2015)—and the lack of
ChIP-grade antibodies against TET2. To circumvent this, we used
CRISPR homology-directed repair to introduce ChIP-verified epi-
tope tags into the endogenous Tet2 locus in murine ES cells. We
identified, upon clonal expansion and characterization, two inde-
pendent lines with in-frame integration of a V5-tag or a 2xFLAG
(2xFL)-tag at the C terminus of Tet2 (Supplemental Fig. S1A,B).
Analysis of ChIP coupled with high-throughput sequencing
(ChIP-seq) using V5 or FLAG-specific antibodies revealed that the
presence of the protein–protein crosslinker disuccinimidyl gluta-
rate (DSG) in combination with formaldehyde (FA) greatly in-
creased the signal-to-noise ratio of the ChIP signal (Fig. 1A) and
increased the number of called peaks (Fig. 1B). In contrast,
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Figure 1. TET2 chromatin immunoprecipitation and sequencing on wild-type and epitope-tagged cell lines. (A) Representative ChIP-seq tracks of either
V5 (left) or 2xFL (right) ChIP experiments in ES cells using different crosslinking conditions. (FA) formaldehyde; (DSG) disuccinimidyl glutarate; (EGS) eth-
ylene glycol bis(succinimidyl succinate). (B) Histograms showing the number of called peaks in the different crosslinking conditions in V5-TET2 (upper) or
2xFL-TET2 (lower)-expressing cells compared to parental cells without endogenously tagged TET2. The number of peaks enriched in parental cells are also
shown (inverse peak calling). (C) ChIP-qPCR for TET2 binding in ES cells using antibodies raised against endogenous TET2. Two positive regions (an intronic
DNase I hypersensitivity site in Tet3 and an enhancer region in theManba gene) as well as a negative control region are shown. Data are presented asmean
enrichment over input with error bars depicting technical triplicates. The average fold enrichment over Tet2 knockout control cells is indicated.
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crosslinking conditionswith formaldehyde alone, or the combina-
tionof the longerethyleneglycolbis(succinimidyl succinate) (EGS)
crosslinker plus formaldehyde, were insufficient to capture these
regions.
Encouraged by these results, we tested if untagged endoge-
nous TET2 could bemapped to chromatin using these crosslinking
conditions. ES cell chromatin was crosslinked with DSG+FA and
immunoprecipitation was performed using an antibody raised
against the N terminus of TET2 (TET2-N) or a commercially avail-
able antibody directed against the TET2 C terminus (TET2-C). We
observed a strong and reproducible enrichment of TET2-bound re-
gions using the TET2-N antibody, and this signal was absent in
knockout cells or at a negative control region (Fig. 1C). Thus, the
combination of specific antibodies and optimized workflows al-
lows for the precise mapping of TET2-bound genomic regions.
TET2 binds regions of open chromatin with enhancer features in
embryonic stem cells
Next, we generated a high-quality ChIP-seq data set to determine
genome-wide TET2 occupancy in ES cells. Quality control of bio-
logical duplicate experiments using antibodies to endogenous
TET2 (TET2-N)or the FLAG-taggedTET2expressed fromthe endog-
enous locus (FLAGM2) showed excellent correlation between rep-
licate samples (Supplemental Fig. S1C–F). To avoid the false
discovery of “phantom peaks,” TET2 binding sites were defined
by enrichment over nonspecific ChIP-enriched regions identified
in Tet2 knockout cells or parental cells without FLAG-tagged
TET2. In total, this analysis revealed 26,512 TET2-bound regions
of which approximately one-third, referred to as “high-confi-
dence” TET2 binding sites, were identified with both antibodies
and had a stronger ChIP-seq signal (Fig. 2A; Supplemental Fig.
S1G,H). Thevastmajority (93.4%)of these8262 siteswere localized
in regions of open chromatin defined by DNase I hypersensitivity
(DHS) (Fig. 2B,C).
To understandwhether TET2 is enriched in specific regions of
open chromatin in the genome, we compared TET2 binding sites
to sets of random control regions (×5) matched for size, orienta-
tion, and distance to DHS sites. This showed a strong enrichment
of TET2 high-confidence binding sites at DHS with enhancer fea-
tures such as EP300 binding (fourfold), H3K27ac (2.5-fold), and
H3K4me1 (1.6-fold), whereas TET2 binding at promoters, CpG is-
lands, and CTCF binding sites was depleted (∼0.3-fold each) (Fig
2D). In agreement with this, we found that TET2 binding sites
were located in CpG-sparse regions as compared to CpG islands
(Supplemental Fig. S1I). This binding pattern is furthermore illus-
trated by a representative TET2-bound enhancer region 10 kb up-
stream of the master ES cell regulator Zfp281 (Fig. 2E). In total,
up to 90% of TET2 binding sites are associated with features of dis-
tal regulatory elements (EP300, H3K27ac, H3K4me1, or DHS), and
nearly half of TET2-bound regions overlap with promoter-distal
EP300 binding sites (Fig. 2F). Chromatin occupancy of EP300 is a
hallmark of active enhancers, and a biochemical interaction be-
tween EP300 and TET2 has recently been reported (Heintzman
et al. 2007; Zhang et al. 2017). Thus, our data are in agreement
with a model in which TET2 can be directly recruited to a subset
of its chromatin targets via a direct interaction with EP300
(Zhang et al. 2017).
A previous study examined the genome-wide changes in
5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC)
that occur upon Tet2 knockout in ES cells (Hon et al. 2014). We
used this data set to identify epigenetic changes around (±250
bp) high-confidence TET2 binding sites. Genetic knockout of
Tet2 is likely to result in gain of 5mC (due to absence of DNAdeme-
thylation), loss of 5hmC (stable product of methylcytosine oxida-
tion by TET2), or both, at sites of TET2 recruitment. We did not
observe a linear correlation between TET2 binding and changes
in DNA methylation in Tet2 knockout (Supplemental Fig S1J,K).
However, we found DNA methylation changes consistent with
loss of TET2 catalytic activity (hyper-5mC, hypo-5hmC, or both)
at the majority of high-confidence TET2 binding sites (∼93%)
(Fig. 2G), thereby confirming that TET2modifies theDNAmethyl-
ation state. The analysis was repeated with the full set of 26,512
sites with evidence of TET2 binding (Supplemental Fig. S2A).
Within this larger and less stringent set of regions, we observed a
modest enrichment of TET2 binding at CpG islands and gene pro-
moters (Supplemental Fig. S2B). However, in contrast to a pro-
nounced DNA hypermethylation at sites cobound by TET2 and
EP300, DNA methylation did not change at these CpG islands
and promoters in Tet2-deficient ES cells (Supplemental Fig. S2C,
D). This is consistent with the previously identified role of TET2
inmaintaining a low level of DNAmethylation at distal regulatory
elements, whereas CpG islands and promoters are protected from
DNA hypermethylation by additional mechanisms (Rasmussen
and Helin 2016). It should be noted that most differentially meth-
ylated regions reported in Tet2 knockout ES cells (over 60,000 hy-
per-DMRs and 130,000 hypo-DMRs) (Hon et al. 2014) did not
show detectable binding of TET2 in our data set (Supplemental
Fig. S2E). This suggests that TET2 functions in the absence of ro-
bust and persistent binding at these sites and that some of these
methylation changes (especially hypo-DMRs) canoccur as a conse-
quence of secondary events to TET2 depletion, or as a result of cell
passaging (misincorporation during DNA replication) (Rasmussen
et al. 2015). Taken together, our data show that TET2 binds to re-
gions of open chromatin with enhancer features that undergo
TET2-dependent DNA demethylation.
Cell-type–specific binding pattern of TET2 in myeloid
hematopoietic versus ES cells
Next, we determined the genome-wide binding sites of TET2 in he-
matopoietic cells. To this end, we usedmyeloid cells immortalized
by AML1-ETO with the potential for inducible deletion of Tet2
(Tet2fl/fl;AE;Rosa26+/CreERT2) (Rasmussen et al. 2015). Analysis of
biological duplicate ChIP experiments using the TET2-N antibody
(ChIP using a FLAG-tagged version of TET2 was not performed
because this would require generating a novel FLAG-tagged Tet2
mouse line) identified 19,706 regions significantly enriched
over knockout control. In total, only 7.4% of these regions were
shared between ES cells and myeloid cells (Fig. 3A; Supplemental
Fig. S2F,G).
We then overlapped the TET2myeloid binding sites with var-
ious genomic regions. Although binding of TET2 could be detect-
ed in a subset of promoters and CpG islands, the majority of
binding sites was promoter-distal (67.4%), and nearly half
(44.4%) were associated with enhancer features (Fig. 3B). An illus-
trative example of this binding pattern is shown at enhancers up-
stream of the hematopoietic master regulator Gata2 (Fig. 3C).
Since promoter DNA methylation patterns are largely unaffected
by depletion of TET2 (Rasmussen et al. 2015), we decided to focus
our analysis on promoter-distal TET2 binding sites. Identification
of enriched Gene Ontology (GO) terms by Genomic Regions
Enrichment of Annotations Tool (GREAT) (McLean et al. 2010) re-
vealed a striking separation by cell type. For example, the
Rasmussen et al.
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GO terms “stem cell maintenance” and “blastocyst formation”
were enriched for TET2 binding sites in ES cells, whereas “immune
system process” was highly significant for sites in myeloid cells
(Supplemental Fig. S2H,I). Next, we performed motif enrichment
analysis of known DNA-binding TFs. The top enriched motifs
belonged to master TFs of the respective cell types such as SOX2,
KLF4, ESRRG, POU5F1, and NANOG in ES cells, and ERG,
RUNX1, CEBPA, and GATA1 in myeloid cells (Fig. 3D,E).
Together, these results indicate that TET2 is recruited to chromatin
in a highly cell-type–specific manner and that TET2 binding at
promoter-distal regulatory elements colocalizes with a wide range
of predicted TF binding sites.
Differential analysis of chromatin accessibility reveals widespread
changes in TF activity upon TET2 loss
Analysis of chromatin accessibility in gene regulatory regions can
be used as a genome-wide and locus-specific measure of nonhis-
tone protein binding to DNA (Hesselberth et al. 2009). It therefore
offers an opportunity to systematically assess whether particular
sets of TFs (as defined by chromatin accessibility changes at their
DNA-binding motifs) are affected by loss of TET2 and potentially
drive the genomic and phenotypic changes observed in TET2-
mutated hematopoietic cells. Therefore, we decided to perform ge-
nomic profiling by Assay for Transposase Accessible Chromatin
E
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Figure 2. TET2 binds regions of open chromatin with enhancer features in ES cells. (A) Venn diagram showing overlap of called peaks in TET2-N or FLAG
M2 ChIP-seq experiments (left) as well as average ChIP signal from replicate samples (right). High- and low-confidence TET2 binding sites are defined, re-
spectively, as regions showing evidence of TET2 binding in both peak sets (high) or only supported by a called positive region in one peak set (low). (B) Heat
maps of ChIP-seq signal fromwild-type TET2 or TET2 with two copies of a FLAG tag (2xFL). Tracks of H3K27ac and EP300 enrichment as well as regions of
DHS in ES cells are also shown. The vertical axis contains all high-confidence TET2 binding sites defined in A, sorted by decreasing EP300 read counts. The
horizontal axis is centered on TET2 peaks. (C) Histogram showing overlap of high-confidence TET2 binding sites with regions of DHS in ES cells. Random
matched control regions (Control) were generated with same size, orientation, and distance relative to gene bodies. (D) Histogram showing overlap as C
but with randommatched control regions relative to DHS. The percentage of CpG islands, proximal (±250 bp) or distal (±1500 bp) transcription start sites
(TSS), EP300 binding sites, H3K27ac, and H3K4me1 enriched domains, Gene body, and CTCF binding sites, overlapping TET2 high-confidence binding
sites are shown. Data indicate the number of TET2 BS overlapping a given region set divided by the total number of loci in the region set (e.g., 175,237 DHS
in ES cells) and fold enrichment over matched control are stated (red). (E) Representative ChIP-seq tracks showing a TET2-bound region upstream of the
Zfp281 gene in ES cells. (F) Pie chart showing the distribution of high-confidence TET2 binding sites with respect to the indicated genomic regions. Each
TET2 binding site is counted only once and excluded whenmoving clockwise from proximal promoters (e.g., 8% of TET2 high-confidence BS overlap with
DHS but does not overlap with any of the preceding genomic elements). Blue hues indicate the fraction of TET2-bound regions with regulatory potential at
promoter-distal sites (∼90%of all TET2-bound regions). (G) Pie chart as in F showing average change in DNAmethylation (5mC and 5hmC) upon TET2 loss
in ES cells (whole-genome bisulfite sequencing data [WGBS] from Hon et al. 2014) in high-confidence TET2 binding sites and flanking regions (±250 bp).
Only CpG sites covered by more than 10 reads were included in the analysis. Each TET2 binding site is counted only once and excluded when moving
clockwise. Red hues indicate the fraction (∼93%) of TET2-bound regions showing DNA methylation changes consistent with loss of TET2 catalytic activity
(gain or 5mC or loss of 5hmC, or both). Regions in B–F enriched for DHS, EP300, H3K27ac, H3K4me1, and CTCF sites in ES cells were experimentally de-
termined in the ENCODE Project (The ENCODE Project Consortium 2011).
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and sequencing (ATAC-seq) inmouse ES cells aswell as three differ-
ent Tet2 knockout hematopoietic cell types—Multipotent progen-
itors (MPPs), Granulocyte-Monocyte progenitors (GMPs), and
acute myeloid leukemia (AML) cells (Fig. 4A,B; Supplemental Fig.
S3A,B).
Analysis of regionswithdifferential chromatin accessibility in
MPPandAMLcells revealed that themajorityofdifferential regions
(∼75%)were less accessible inTet2-deficient cells. In addition, 88%
of peaks with loss of DNA accessibility inMPP cells were associated
with increased DNAmethylation in hematopoietic stem cells with
ablation of TET activity (Supplemental Fig. S3C; An et al. 2015).
Finally, a considerable fraction of these peaks in both MPP and
AML cells (30%–40%) overlapped with previously annotated en-
hancers in blood lineages (Fig. 4C,D,F; Lara-Astiaso et al. 2014).
This suggests that increased DNA methylation plays a direct role
in restricting DNA binding within these
regions. In contrast, differentially accessi-
ble regions in GMPs were balanced
between higher and lower chromatin ac-
cessibility (Fig. 4E). To gain further in-
sight into this, we overlapped ATAC-seq
differential regions in GMPs with TET2
ChIP data obtained from the GMP-like
myeloid hematopoietic cells. We found
significantly higher normalized TET2
read counts in regions with reduced ac-
cessibility uponTet2 knockout compared
to those with increased accessibility
(Supplemental Fig. S3D). This suggests
that TET2 is likely to have a direct role
to maintain open chromatin (and TF
binding), whereas the increases in chro-
matin accessibility at other regions may
be due to accumulated epigenetic dysre-
gulation or associated secondary events
in response to TET2 loss (e.g., imbalance
of differentiation-associated cytokines
and growth factors).
To identify TF binding events that
are affected by TET2 loss in native
chromatin, we developed a novel com-
putational method, diffTF (Berest et al.
2018), to assess “TF activity” on a ge-
nome-wide scale using profiles of chro-
matin accessibility by ATAC-seq. In this
method, we compare the accessibility
changes at putative binding sites within
ATAC-seq peaks for each TF and compare
this distribution to the background
distribution of accessibility fold changes
for all other TFs. If the putative binding
sites of a TF are overall less open in the
Tet2 mutant cells, we define this TF to
be less “active” in Tet2 knockout cells
and vice versa. Thus “TF activity” is here
defined as the TF being associated with
increased chromatin accessibility at its
target sites. We predicted differential TF
activityusingacomprehensive collection
of DNA-binding motifs for mouse TFs
(Kulakovskiy et al. 2016). However, al-
though this analysis identifiednumerous
TFs with altered activity in one or several cell types, the high simi-
larity of DNA-binding motifs in groups of related TFs (e.g., GATA
family)makes it challenging topinpoint anobserved effect to a sin-
gle group member. Therefore, we clustered TFs based on similarity
of DNA-bindingmotifs (Supplemental Table S1) and compared the
overall differential activity of clusters in wild-type and Tet2 knock-
out (Fig. 5A,B).
Loss of TET2 resulted in widespread changes in TF activity in
all observed cell types. InGMP cells, we detected a strong signature
of aberrant lineage differentiation characterized by increased activ-
ity of the IRF family of TFs (Cluster 18) and decreased activity of
GATA family members (Cluster 3). Conversely, MPP cells showed
a pronounced increase in chromatin accessibility in predicted
binding sites of the GATA and CCAAT/Enhancer binding protein
family (Clusters 3 and 23) and AML, GMP, and MPP cells were
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Figure 3. Cell-type–specific binding pattern of TET2 in myeloid hematopoietic cells. (A) Venn diagram
showing overlap of TET2 binding sites in ES cells and myeloid hematopoietic cells. Binding sites are de-
fined from biological replicate samples by enrichment over nonspecific ChIP-enriched regions in Tet2
knockout cells using the TET2-N antibody. (B) Pie chart showing distribution of TET2-bound regions in
myeloid hematopoietic cells. Each TET2 binding site is counted only once and excluded when moving
clockwise from proximal promoters (e.g., 10.1% of TET2 BS overlap with DHS but does not overlap
with any of the preceding genomic elements). Blue hues indicate fraction (∼44%) of TET2-bound regions
with regulatory potential at promoter-distal sites based on H3K27 acetylation and H3K4 methylation in
myeloid cells as well as DHS in the relatedmouse erythroleukemia (MEL) cell line. (C) Representative ChIP-
seq tracks showing TET2-bound enhancer regions upstream of theGata2 gene inmyeloid hematopoietic
cells. (D) List of top enriched logos and their associated DNA-binding TFs identified in promoter-distal
(−1.5 kb/+500 bp from TSS) TET2-bound regions in ES cells. (E) As in D, but for myeloid hematopoietic
cells. Regions in B and C enriched for H3K27ac, H3K4me3, and H3K4me1 were experimentally deter-
mined in Rasmussen et al. (2015), and DHS in MEL cells was downloaded from the ENCODE Project
(The ENCODE Project Consortium 2011).
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characterized by a loss of activity of members of the HOX protein
family (Cluster 8). Finally,Tet2 knockout ES cells exhibited a prom-
inent decrease in activity of a large TF cluster containing steroid
hormone receptors including estrogen receptor alpha (Cluster 6).
Several recent studies are consistent with a direct role of DNA
methylation and TET2 catalytic function to facilitate activity
and/or expression of members of these TF clusters: (1) CEBPB
has been reported to have a preference for binding to motifs
with a methylated cytosine, thus poten-
tially implicating TET2 as a factor that
restricts C/EBP family TF binding to chro-
matin (Mann et al. 2013; Zhu et al. 2016);
(2) consistent with loss of HOX gene ac-
tivity in AML cells, TET2 catalytic activity
has been implicated in maintenance of
expression of the HOXA cluster in vari-
ous cell types (Bocker et al. 2012); and
(3) TET2 has recently been shown to me-
diate recruitment of estrogen receptor
alpha by demethylation of estrogen re-
sponsive enhancers in the breast cancer
cell line MCF-7 (Wang et al. 2018).
Together, these results suggest that loss
of TET2 catalytic activity, and the result-
ing alterations in DNA methylation and
hydroxymethylation, has pleiotropic ef-
fects on chromatin accessibility and TF
binding, most likely related to cell-type–
specific chromatin structure and TF ex-
pression patterns.
Basic helix–loop–helix (bHLH) TFs
are adversely affected by loss of TET2
in hematopoietic cells
To understand whether the observed
TF activity changes could potentially
explain the altered hematopoietic dif-
ferentiation program observed in Tet2
knockout hematopoietic cells, we fo-
cused on a cluster of basic helix–loop–he-
lix (bHLH) TFs (Cluster 12), whose
activity was consistently decreased upon
TET2 loss in all cell types and this
decrease was observed at sites of TET2
binding (e.g., see “AML.ChIP” and
“ES.ChIP”) (Fig. 5A,B).Cluster 12 consists
of 22 TFs that preferentially bind enhanc-
er-box (E-box) elements (5′-CANNTG-3′)
in the genome. E-box motifs often con-
tain a central CpG site, and 5mC, as well
as the TET-mediated oxidation products
5hmC and 5fC, in this motif have been
shown to impair in vitro DNA binding
(Wang et al. 2017; Yin et al. 2017).
Analysis of mRNA expression of Cluster
12 TFs in MPP cells revealed that the
most abundantly expressed TFs were the
MYC/MAX, MAX/MXI1, and HIF1A/
ARNT heterodimers, as well as the E pro-
teins ITF2 and ZEB1. Therefore, it is likely
that the observed changes in chromatin
accessibility originate from altered binding activity of these TFs as
other Cluster 12 TF members are lowly expressed or absent (Fig.
5C). None of the abundant TFs were found to be differentially ex-
pressed in Tet2 knockout MPP cells, thus suggesting that loss of
TET2 results in decreased TF binding activity rather than inducing
changes in TF expression (Fig. 5D).
We reasoned that a potential loss of TF binding may result in
decreased expression of TF target genes. To analyze the effect of TF
E
F
BA
C D
Figure 4. Differential analysis of chromatin accessibility reveals widespread changes in TF activity upon
TET2 loss. (A) Diagram showing experimental setup to analyze native hematopoiesis in aged Tet2-defi-
cient animals (see also Supplemental Fig. S3A). It has been demonstrated that native hematopoiesis is
predominantly sustained by multipotent progenitors (MPPs) throughout the lifetime of the mouse
(Sun et al. 2014; Busch et al. 2015). We therefore decided to perform genomic profiling on wild-type
and Tet2-deficient MPPs as well as downstream myeloid-lineage progenitors (Granulocyte-Monocyte
Progenitors [GMPs]). (B) Diagram showing experimental setup to analyze AML cells with and without
deletion of Tet2. Genetically engineered mouse models (Lee et al. 2007; Quivoron et al. 2011;
Vassiliou et al. 2011) carrying the indicated alleles were crossed andmonitored for disease development.
TheNpm1+/cA;Flt3+/ITD genotype is sufficient to induce lethal AML (Mupo et al. 2013); however, ablation
of Tet2 accelerates the onset of disease. Leaky Cre activity induces AML formation in the absence of
pIpC-mediated induction of Mx1-Cre recombinase (Velasco-Hernandez et al. 2016). ATAC-seq analysis
was performed on in vitro-grown leukemic progenitor cells isolated by FACS (see also Supplemental
Fig. S3B). (∗∗∗∗) P<0.0001 (Log-rank [Mantel-Cox] test) in Kaplan-Meier plot. (C–E) Histogram showing
the number of regions with significantly altered chromatin accessibility (FDR<0.05) identified by diffBind
analysis of wild-type and Tet2 knockout MPP cells (n =4) (C), AML cells (n=3) (D), and GMP cells (n=4)
(E). Pie charts indicate distribution of regions with decreased chromatin accessibility (down peaks) in Tet2
knockout cells with respect to promoters, CpG islands, and blood lineage enhancer regions (Lara-Astiaso
et al. 2014). (F) Tracks of ATAC-seq signal in MPP cells from individual wild-type and Tet2 knockout an-
imals (n =4) at three representative genomic loci. Peaks that overlap a blood lineage enhancer with sig-
nificantly decreased ATAC-seq reads in Tet2 knockout animals are highlighted in gray.
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binding on gene expression, we generated expression profiles from
wild-type andTet2 knockoutMPP cells and determined the expres-
sion of genes within 100 kb of the predicted TF binding sites. This
analysis revealed that loss of TET2 leads to decreased expression of
geneswith predicted ITF2 binding sites (Fig. 6A). In support of this,
we also observed a decrease in expression
of the validated ITF2 target genes, Ccr9
and Dntt, in Tet2 knockout MPPs (Fig.
6B), and analysis of DNA methylation
changes in predicted ITF2 binding sites
revealed an overall increase in 5mC levels
in hematopoietic stem cells upon abla-
tion of TET activity (Fig. 6C).
Mice with hematopoietic-specific
knockout of a single allele of Itf2 display
defects in differentiation of plasmacytoid
dendritic cells (pDCs) (Cisse et al. 2008).
Therefore, we reasoned that a change in
ITF2 binding activity should recapitulate
this. Phenotypic analysis of aged Tet2
knockout mice revealed a partial im-
pairment of pDC development that is
highly similar to previously published
observations in Itf2 heterozygous knock-
out bone marrow (Fig 6D,E; Cisse et al.
2008). Overall, these results suggest that
the knockout of Tet2 phenocopies the
haploinsufficiency of Itf2 in hematopoi-
etic stem cells by decreasing the binding
activity of ITF2 rather than changing its
expression. This would derail normal
pDC differentiation in the bone marrow.
Frequent mutations of TET2 have been
found in patients with Blastic plasmacy-
toid dendritic cell neoplasm (BPDCN), a
rare myeloid neoplasm characterized by
proliferation of aberrant pDC precursor
cells (Scourzic et al. 2015). Thus, TET2
may prevent BPDCN by keeping the
binding sites of ITF2 accessible and thus
maintaining the expression of ITF2-regu-
lated genes.
Within Cluster 12, MYC was by far
the most abundantly expressed TF in he-
matopoietic stem cells. It has previously
been reported that DNA methylation in-
hibits MYCN chromatin binding in
Tet1-3 triple knockout ES cells (Yin et al.
2017), and a recent study has uncovered
that TET2 is recruited to MYC binding
sites by SNIP1 in cancer cell lines (Chen
et al. 2018). However, analysis of chro-
matin accessibility by diffTF at MYC
binding sites (predicted individually
from all available MYC DNA-binding
motifs) did not show a significant differ-
ence in wild-type and Tet2 knockout,
possibly due to a complex MYC binding
pattern at E-boxes throughout the ge-
nome. To further analyze if MYC activity
could be affected by TET2, we performed
gene set enrichment analysis (GSEA) on
RNA-seq data from wild-type and Tet2 knockout MPP cells. This
analysis revealed a pronounced down-regulation of MYC target
gene signatures (Fig. 6F; Supplemental Table S2; Menssen and
Hermeking 2002; Zeller et al. 2003). Furthermore, we also found
a general down-regulation of gene signatures of translation,
BA
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Figure 5. Summary of diffTF analysis and ATAC-seq profiles of multiple cell types with loss of TET2.
(A) The heatmap represents the summary of diffTF analyses between Tet2 knockout and wild type across
multiple cell types. The color scale of the heatmap corresponds to the Z-scores of the weighted mean
difference values (TF activity) obtained from diffTF. Negative values indicate that the TF cluster has lower
activity in Tet2 knockout samples compared to the wild type, and vice versa for positive values. Only TF
clusters with three or more TFs are shown. For each cell type, the analysis was run on different sets of
peaks: promoter regions only (−1.5 kb/+500 bp from TSS; labeled celltype.Pro) and putative enhancer
regions (+100 kb/−100 kb from TSS excluding promoter regions; celltype.ProDist), in addition to the
full set of peaks (celltype.all). For the cell types for which we mapped TET2 binding sites by ChIP-seq
(ES cells and AML cells), diffTF was also run using ATAC-seq peaks intersected with TET2 ChIP in the cor-
responding cell type (celltype.CHIP). TET2-bound regions in AML cells were determined in bulk AML cells
(containing both the leukemic precursor population that was used for ATAC-seq analysis as well as more
differentiated cells) (Supplemental Fig. S3B). (B) Box plot showing weighted mean difference values ob-
tained from diffTF analyses for each TF cluster in MPP cells comparing Tet2 knockout versus wild type.
Individual TFs within a cluster are shown (black dots), and TFs passing a significance threshold (P-val-
ue <0.1) are highlighted (red dots). The predominant TF identity of selected clusters (12, 3, and 23)
are marked. (C) Histogram showing mean normalized counts for Cluster 12 TFs obtained from RNA-
seq data generated from wild-type and Tet2 knockout MPP cells (n=4). The TFs within Cluster 12 are
ranked based on mean normalized abundance. (D) DESeq2 differential expression values of Cluster 12
TFs ranked as in C. No statistically significant changes were observed (FDR <0.05).
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ribosome biogenesis and metabolism, which are processes known
to be controlled by MYC (Fig. 6G; Supplemental Table S2). Thus,
transcriptome analysis suggests that MYC activity is indeed ad-
versely affected in Tet2 knockout MPP cells, likely through altered
DNAmethylation at MYC target sites and decreasedMYC TF chro-
matin binding. In support of this, conditional knockout ofMychas
been shown to result in hematopoietic stem cell expansion
(Wilson et al. 2004) similar to what has
been observed in aged Tet2 knockout an-
imals (Moran-Crusio et al. 2011;
Quivoron et al. 2011). Together, these re-
sults suggest that impairment ofMYC ac-
tivity may confer a competitive
advantage to Tet2 knockout hematopoi-
etic stem cells, and that impairment of
other bHLHTFs, such as ITF2, renders ter-
minal differentiation inefficient.
Discussion
Although DNA methylation landscapes
in TET2 mutant cells have been exten-
sively characterized (Koet al. 2010;Asmar
et al. 2013; Hon et al. 2014; Rasmussen
et al. 2015; Yamazaki et al. 2015), much
less is known about the functional conse-
quences thatultimatelydrivehematopoi-
etic stem cell expansion andmalignancy.
Here, we resolve the inconsistency be-
tween regions reported to be bound by
TET2 (Chen et al. 2013; Deplus et al.
2013; Peng et al. 2016) and those affected
by TET2 catalytic function.We show that
TET2 is predominantly recruited to pro-
moter-distal regions of open chromatin,
including enhancers. Therefore, it is like-
ly that it is epigenetic perturbation of
these elements that results in dysregu-
lated hematopoiesis of TET2-mutated
stem cells, possibly through pleiotropic
effectsonmanygenes that togetherderail
homeostasis and differentiation. A recent
study has reported a direct biochemical
interaction between the histone acetyl-
transferase EP300 and TET2 (Zhang
et al. 2017). In ES cells, we find that ap-
proximately half of high-confidence
TET2 binding sites colocalize with pro-
moter-distal EP300-enriched regions
(Fig. 2B,F), and nearly half of all EP300-
enriched regions show evidence of TET2
binding (Supplemental Fig. S2B). Taken
together these results may suggest that
EP300 is involved in recruiting TET2 to
chromatin through direct protein–pro-
tein interactions. However, a direct vali-
dation of this and a comprehensive
analysis of the role of additionalpotential
recruiters, such as WT1 (Rampal et al.
2014; Wang et al. 2015), remain an area
of active investigation.
To dissect the impact of TET2 loss in
hematopoiesis, we investigated genome-wide changes in enhancer
function using chromatin accessibility as a measure of activity in a
native chromatin context. We report widespread changes, of
which a majority of differentially open regions in all tested cell
types, except GMP, were less accessible upon ablation of TET2.
This is consistent with a recent study showing that most DNA
methylation-sensitive regulatory elements (∼86%) are inhibited
E
F
BA
C
D
G
Figure 6. Basic helix–loop–helix (bHLH) TFs are adversely affected by loss of TET2 in hematopoietic
cells. (A) Correlation of changes in TF activity and target gene expression. The scatter plot shows a pos-
itive correlation (Pearson’s r=0.4; P-value < 0.005) between differential TF activity, as defined by diffTF,
and themedian log2 fold change of putative target genes (TF binding sitewithin ±100 kb of the promoter
region) of the same TF. The accentuated vertical line represents the median expression of all target genes
used in the analysis. (B) DESeq2 expression values from RNA-seq in MPPs showing expression of Itf2
(gray) and the two validated ITF2 target genes Dntt and Ccr9 (red). Data are presented as mean± SEM
(n=4). (ns) not significant; (N/D) not calculated due to outlier sample; (∗) P<0.05 (Q-value). (C ) Box
(left) and scatter plot (right) showing average 5mC changes at predicted ITF2 binding sites in wild-
type and Tet2/Tet3 double knockout (T2/T3 dKO) LSK (LineagenegSca1+cKit+) cells (An et al. 2015).
Box plot shows median (red line) and 25th and 75th quantile, and the scatter plot shows 5mC changes
for individual ITF2 sites. Only CpG sites covered by more than 10 reads were included in the analysis.
(∗∗∗∗) P<0.0001 (paired two-tailed Student’s t-test). (D) Representative FACS plots showing the popula-
tion of plasmacytoid dendritic cells (pDC) in bone marrow of aged wild-type and Tet2-deficient animals.
(E) Scatter dot plots showing the percentage (left) and absolute cell count (right) of pDCs in the
bone marrow of aged wild-type and Tet2-deficient animals. Line and error bars represent mean ± SD
(n=5–6). (∗) P<0.05; (∗∗) P<0.01 (unpaired two-tailed Student’s t-test). (F ) Enrichment plots from
GSEA showing decreased expression of MYC target genes in Tet2-deficient MPP cells (Menssen and
Hermeking 2002; Zeller et al. 2003). (G) Enrichment plots from GSEA showing decreased expression
in Tet2-deficient MPPs of genes involved in ribosome biogenesis and translation (see Supplemental
Table S2 for full list of gene signatures).
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by DNA methylation (Lea et al. 2018). To perform an unbiased
analysis of TF signatures that were globally enriched or depleted,
we developed a novel computational tool, diffTF, to assess differen-
tial TF binding from ATAC-seq profiles (Berest et al. 2018). We
could detect signatures of aberrant activity of several clusters of he-
matopoietic TFs such as IRF, C/EBP, GATA, and HOX protein fam-
ilies in different hematopoietic cell types. In addition to these
changes, we also found a strong and consistent loss of activity
for a cluster of bHLH TFs (including MYC and ITF2) that preferen-
tially bind enhancer-box (E-box) elements in the genome. To ex-
amine the molecular and phenotypic consequences of this, we
uncovered that (1) MYC and ITF2 target genes were down-regulat-
ed in Tet2 knockout hematopoietic stem cells; (2) ITF2 binding
sites were DNA hypermethylated upon ablation of TET activity;
and (3) Tet2 knockout mice show hallmarks of Myc-deficient and
Itf2-deficient hematopoiesis. Thus, our results support a model
by which TET2 recruitment and catalytic functions are necessary
to shape the chromatin structure for permissive TF binding.
It should be noted that although inferring differential TF oc-
cupancy from ATAC-seq data provides a global view of the tran-
scriptional network of a cell, it does have limitations: The use is
dependent on collections of TF binding motifs of high quality
(not applicable to TFs with poorly defined or unknownDNA-bind-
ingmotifs) as well as the inherent impact of binding of specific TFs
on nucleosome density. For instance, it is possible that additional
TF binding events that were not identified in this study may also
require TET2 activity; however, such TFs may not show strong
global differences or are not detected from TF motif analysis of
chromatin accessibility alone. Vice versa, due to the high similarity
of DNA-binding motifs within certain TF families, the role of a TF
identified by this approach should subsequently be characterized
to confirm the identity as well as the biological significance.
Frequentmutations in theDNAmethylationmachinery have
been found in patients suffering from hematological diseases as
well as solid cancers (Rasmussen and Helin 2016). Yet, whether
DNA methylation is causally involved in shaping gene expression
patterns, rather than passively mirroring transcriptional states, is
still a matter of debate (Schübeler 2015). Here, we present data in
support of a role of TET2-mediated cytosine modifications at en-
hancers to facilitate TF binding and fidelity of target gene expres-
sion in hematopoietic cells. Rather than being an obligate
activator, TET2 functions to reinforce binding of some TFs and
contributes in this manner to enhancer activity and gene expres-
sion. Analysis of chromatin maturation after replication fork pas-
sage has indicated that open chromatin at cell-type–specific
enhancers are only slowly reestablished through competition of
TFs with newly deposited nucleosomes (Ramachandran and
Henikoff 2016). Thus, cells that naturally divide rapidly and
must undergo coordinated cell state transitions (e.g., hematopoiet-
ic stem and progenitor cells) may be particularly sensitive to
epigenetic disturbances of TF binding kinetics. Comprehensive
analysis of enhancer function in TET2-mutated hematopoiesis
will foster a greater understanding of the role of epigenetic dysre-
gulation in disease andmay lead to discoveries of potential clinical
significance.
Methods
ES cell lines
Mouse ES cell lines were derived from blastocysts harvested
from Tet2fl/fl animals (Moran-Crusio et al. 2011). To generate a
clean Tet2 knockout ES cell line (to use as ChIP control), cells
were transiently transfected with a Cre recombinase-expressing
plasmid and subcloned to identify a constitutive Tet2 knockout
ES cell line. Endogenous tagging of TET2 was performed using
CRISPR homology-directed repair with a single-stranded DNA
oligonucleotide repair template. Briefly, a sgRNA targeting the
insertion site was cloned into pSpCas9(BB)-2A-GFP (PX458)
(Addgene #48138). This plasmid was cotransfected in ES cells
with oligonucleotides encoding either two copies of Flag
(DYKDDDDKDYKDDDDK) or a single copy of V5 tag (GKPIPNPL
LGLDST) as well as homology arms (60 bp each). Transfected cells
were single-cell sorted, and the resulting clones were screened for
stable expression of epitope-tagged TET2 by Western blot. All
mouse ES cell lines were cultured in feeder-free, gelatinized plates
in “Serum/2i/LIF” conditions: Dulbecco’s Modified Eagle Medium
(DMEM) supplementedwith 15% fetal bovine serum, 2mMGluta-
max (Gibco), 0.1 mM2-Mercaptoethanol (Gibco), 1× nonessential
amino acids (Gibco), 1× Pen/Strep (Gibco), 3 µM GSK3 inhibitor
(CHIR99021), 1 µM MEK1 inhibitor (PD0325901), and leukemia
inhibitory factor (LIF).
Mice
For analysis of aging-related Tet2-deficient hematopoiesis, cohorts
of age-matched litter mates (8-wk old) of Tet2fl/fl or Tet2fl/fl;Mx1-
Cre+ mice (Quivoron et al. 2011) were injected three times intra-
peritoneally with 250 µg polyinosinic-polycytidylic acid (PolyI:C
LMW, InvivoGen) at experimental days 0, 2, and 4. The mice
were subsequently allowed to age and sacrificed at 10 mo of age.
To generate a Tet2 knockout AMLmodel, the following genetically
modified mouse lines Npm1cA-Flox (Vassiliou et al. 2011), Flt3-ITD
(Lee et al. 2007), and Tet2fl/fl;Mx1-Cre+ (Quivoron et al. 2011) were
intercrossed and Npm1+/cA-Flox;Fl3+/ITD;Mx1-Cre+ or Npm1+/cA;
Fl3+/ITD;Tet2fl/fl;Mx1-Cre+ mice were monitored for disease devel-
opment. AML cells were harvested and 2.5×104 c-Kit+Gr1−Mac1−
AML splenocytes transplanted into sublethally irradiated
(650Rad) Ly5.1 recipient animals by tail vein injection. Ly5.1
mice were maintained on medicated water (Ciprofloxacin 100
µg/mL) for 3 wk following the irradiation procedure. To establish
in vitro culture of AML cells, c-Kit+Gr1−Mac1− splenocytes har-
vested from moribund mice were purified by FACS and cultured
in suspension in nontissue culture treated plasticware in
StemPro-34 SFM media (Thermo Fisher Scientific) supplemented
with 2 mM GlutaMAX (Gibco), 1× Pen/Strep (Gibco), 0.1 mM 2-
mercaptoethanol (Sigma-Aldrich), as well as the cytokines SCF
(50 ng/mL), IL3 (10 ng/mL), and IL6 (10 ng/mL) (Peprotech). All
animal work was carried out in compliance with ethical regulation
under license by the Danish regulatory authority.
Chromatin immunoprecipitation and sequencing
ChIP-seq experiments were carried out using a two-step crosslink-
ing procedure with 2 mM disuccinimidyl glutarate (DSG) and 1%
formaldehyde (FA). The genomic coordinates of all region sets de-
rived from TET2ChIP analysis in various cell types can be found in
Supplemental Table S3. See Supplemental Methods for a full de-
scription of experimental protocol, processing, and analysis of
ChIP data sets.
ATAC-seq library generation and analysis
ATAC-seq libraries were generated and sequenced as described pre-
viously (Buenrostro et al. 2013; Lara-Astiaso et al. 2014). See
Supplemental Methods for a full description of experimental pro-
tocol and data preprocessing steps.
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diffTF analysis
In order to define potential difference in TF activity based on the
chromatin accessibility (ATAC-seq) data, we developed a computa-
tional pipeline called diffTF (deposited at https://git.embl.de/grp-
zaugg/diffTF; documented at https://difftf.readthedocs.io) (Berest
et al. 2018). This method takes as input predicted TF binding sites
defined by genome-wide PWM scanner (PWMscan) (Ambrosini
et al. 2018) overlapped with the open regions from ATAC-seq.
For the PWMdatabase source, we usedHOCOMOCOv10 database
(Kulakovskiy et al. 2016), in which we replaced CDX4 and EVX1
motifs (that were retracted from this database) with PWMmodels
from the recent methyl-SELEX study (Yin et al. 2017). We then ex-
tended TF binding sites by 100 bp in each direction and calculated
a fold change of chromatin accessibility between two conditions.
Finally, we removed potential CG-content bias from the data
and used an analytical approach for significance assessment
(Supplemental Methods). The final weighted mean difference val-
ue for each TF corresponds to the genome-wide difference in acces-
sibility between two conditions. We used the matrix-clustering
tool from the RSAT suite (Castro-Mondragon et al. 2017) on the
combined PWM data set with the following parameters: -lth
Ncor 0.4 -lth cor 0.6 and observed 88 clusters of TFs.
External data sets
The following experimentally determined data sets were down-
loaded from the ENCyclopedia Of DNA Elements (ENCODE;
https://www.encodeproject.org/): DNase-seq “ENCFF001YOK”
and “ENCFF00PUJ”, EP300 binding sites “ENCFF001YAD”,
H3K27 acetylation “ENCFF001XWY”, H3K4 monomethylation
“ENCFF001XWY”, and CTCF binding sites “ENCFF001YAC”.
Active and poised enhancers in myeloid hematopoietic cells were
obtained from the NCBI Gene Expression Omnibus (GEO) under
accession number GSE59591. DNA methylation data from wild-
type and Tet2 knockout cells were obtained from GEO: GSE48519
and GSE72630.
Data access
The ChIP-seq, ATAC-seq, and RNA-seq data from this study have
been submitted to the NCBI Gene Expression Omnibus (GEO;
https://www.ncbi.nlm.nih.gov/geo/) under accession number
GSE115972. The source code for the diffTF software used in this
study is available as Supplemental Code and at https://git.embl
.de/grp-zaugg/diffTF.
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